1005342-46-0

Basic information

• Product Name: LCL-161
• Synonyms: LCL-161;N-[(1S)-1-Cyclohexyl-2-{(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]-1-pyrrolidinyl}-2-oxoethyl]-N2-MethylalaninaMide;(2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide;N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-(2S)-propanamide;(2S)-N-[(1S)-1-Cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-2-thiazolyl]-1-pyrrolidinyl]-2-oxoethyl]-2-(methylamino)-propanamide LCL 161;(S)-N-((S)-1-Cyclohexyl-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl);LCL161, 98%, inhibitor of Apoptosis Protein (IAP) family of proteins
• CAS NO: 1005342-46-0
• Molecular Formula: C₂₆H₃₃FN₄O₃S
• Molecular Weight: 500.6286232
• Product Categories: Inhibitors
• Mol File: 1005342-46-0.mol

Chemical Properties

• Boiling Point: 713.7±60.0 °C(Predicted)
• Appearance: /
• Density: 1.245±0.06 g/cm3(Predicted)
• Solubility: ≥25.05 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
• PKA: 14.25±0.46(Predicted)
• CAS DataBase Reference: LCL-161(CAS DataBase Reference)
• NIST Chemistry Reference: LCL-161(1005342-46-0)
• EPA Substance Registry System: LCL-161(1005342-46-0)

Safety Data

• RIDADR: 3077
• Hazardous Substances Data: 1005342-46-0(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
LCL-161 is used as a therapeutic agent in oncology for prolonging patient survival. It is employed to increase the apoptosis induced by anti-tumor drugs, which can lead to a more effective treatment response against cancer cells. By inhibiting IAP family proteins, LCL-161 may help overcome resistance to apoptosis and improve the overall efficacy of cancer treatments.

Upstream product

• 1005342-78-8 C₁₉H₂₁FN₂O₃S 
• 1005342-77-7 tert-butyl (2S)-2-(4-(methoxy(methyl)carbamoyl)-1,3-thiazol-2-yl)pyrrolidine-1-carboxylate 
• 251349-54-9 (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)thiazole-4-carboxylic acid 
• 1005342-82-4 C₃₁H₄₁FN₄O₅S 

Relevant articles and documents

SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF AN INHIBITOR OF APOPTOSIS PROTEIN

The present disclosure relates to crystalline form of (S)-N-((S)-1- cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)- 2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral f

COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS

The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML.